ImmunoGenesis Announces Two Publications Highlighting the Potential of IMGS-203, a Novel Stimulator of Interferon Genes (STING) Agonist, to Overcome Tumor Immune Resistance and Enhance Antitumor Efficacy in Combination with a Cytotoxic Dual-specific PD-L1

Read post on prnewswire.com

HOUSTON, Nov. 5, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced two publications providing new nonclinical evidence and scientific insights into the ability of its novel stimulator of interferon...